Focus on pharma and medtech: Protecting your business
Tokyo Back-to-Business Program Series 2022
1 min read
Life science companies continue to face the challenges of finding new ways to commercialize products and better compete in a more aggressive enforcement landscape, particularly in the US. As a result, pharma and medtech companies must navigate myriad risks in every joint venture, M&A transaction and other business arrangements. In addition to these well-known risks, what additional risks exist when, for example, a company wants to co-commercialize a product with a licensee? If the risk profile, antitrust exposure or IP portfolio of a potential target or counterparty is less than perfect, are there ways to proceed that will protect the company while still allowing an attractive deal to go forward?
In this webinar, our panelists, comprised of White & Case lawyers in antitrust, intellectual property, M&A and white collar practices, will discuss recent developments, strategies for identifying and managing risks that will allow companies to move forward with their business initiatives.
|Time and date||
4 November 2022
Peter Armenio | Partner, White & Case, New York
Peter Carney | Partner, White & Case, Washington, DC
This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2022 White & Case LLP